Kestra Medical Delivers 60% Revenue Growth and Lifts FY27 Guidance to $141M
KMTS sits 34% above its 52-week low of $17.34 on elevated volume (1.9× avg).
Summary
Kestra Medical reported F1Q27 revenue of $31.0 million, up 60% year-over-year, with gross margin expanding to 56.5%. The company raised FY27 revenue guidance to $141 million from $137 million.
Key Events · Earnings and Guidance · KMTS
-
F1Q27 Revenue Up 60%
Revenue reached $31.0 million in F1Q27, up from $19.4 million in the prior year period, driven by WCD market expansion, competitive share gains, new sales territories, and a higher mix of in-network patients.
-
Gross Margin Expands to 56.5%
Gross margin improved to 56.5% from 45.7% year-over-year, reflecting volume leverage, a higher mix of in-network patients, and cost improvement programs.
-
FY27 Guidance Raised to $141M
Kestra increased FY27 revenue guidance to $141 million from $137 million, representing 48% growth over FY26 revenue of $95.1 million.
-
GAAP Net Loss Widens to $44.1M
GAAP net loss was $44.1 million versus $25.8 million in the prior year, including a $6.3 million loss on extinguishment of debt from the July refinancing.
Analysis · KMTS · Industrial Applications And Services
F1Q27 revenue came in at $31.0 million, a 60% year-over-year increase, while gross margin expanded to 56.5% from 45.7%. The company raised its FY27 revenue guidance to $141 million from $137 million, implying 48% growth over FY26. The quarter also included a $6.3 million loss on debt extinguishment tied to the July refinancing, pushing GAAP net loss to $44.1 million. With $244.7 million in cash and investments plus committed term loan availability, total liquidity stands at approximately $320 million — ample runway to fund the commercial expansion and R&D investments driving the top-line acceleration.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KMTS was trading at $23.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $17.34 to $30.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.